RxDoctor Payments Data

Pinkie Fitts

Psychiatric/Mental Health · Aurora, CONPI 1407256217

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $353,887 of the $443,972 with a category attached, or 79.7%. Neurocrine Biosciences, Inc. accounts for 99.3% of it on its own, with 15 other manufacturers making up the rest. 2025 is the largest year on record at $147,456, 3.5 times the $41,843 reported in 2021. Among psychiatric/mental health clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$443,972in general payments, 2019–2025

Across 675 payments — averaging $657.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$441K
  • AbbVie$548
  • Supernus Pharmaceuticals, Inc.$477
  • Alkermes, Inc.$401
  • Bausch Health US, LLC$319
  • Otsuka America Pharmaceutical, Inc.$304
  • plus $1K from 10 others

What the payments were for

  • Consulting fees$20,2515%
  • Speaking & faculty fees$353,88780%
  • Travel & lodging$58,45413%
  • Food & beverage$11,3343%
  • Education$470%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$443,972 in reported general payments places this provider in the 95th percentile of 873 psychiatric/mental health providers in Colorado.

See all psychiatric/mental health providers in Colorado

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate13$102,727
Clozapine22$2,764
Venlafaxine Hcl ErVenlafaxine Hcl14$1,398
Aripiprazole45$949
Dexmethylphenidate Hcl ErDexmethylphenidate Hcl11$921
Desvenlafaxine Succinate ErDesvenlafaxine Succinate11$644
Bupropion XlBupropion Hcl20$607
Trazodone Hcl53$545
Quetiapine Fumarate34$523
Duloxetine Hcl16$448
Risperidone34$398
Lamotrigine25$368
Buspirone Hcl15$329
Fluoxetine Hcl38$280
Sertraline Hcl34$223

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$440,667$102,72713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 873 psychiatric/mental health providers in Colorado.

Other psychiatric/mental health in Aurora

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →